NTHU Accelerator
NTHU has accumulated experience in supporting over 100 startups, with successful cases helping founders grow from seed stage all the way to IPO. At the NTHU Accelerator, we are expanding our startup venture-building services to the global innovation community, offering one-on-one tailored acceleration programs by industry experts based on each team's specific domain, stage, and business model.
10+ years of incubation; 100+ startups supported
One-on-one, tailored programs by domain, stage, and business model
From Seed to Growth — with a long-term view toward IPO readiness
Workspace, entrepreneurship training, and integrated business advisory
Talent, technology, customers, supply chains, and public programs
Customized soft-landing support for international founders entering Taiwan
NTHU’s BNCT commercialization journey- from NTHU’s laboratory research to IPO
Heron Neutron Medical Corp. (Heron Neutron) (https://www.heron-neutron.com/en) is our commercialization case, evolving from academic research to a TFDA-approved product and finally entering the capital market in 2025.
- Building on years of accumulated BNCT research, NTHU completed a key technology transfer in 2018 and spun off Heron Neutron. Following its establishment, Heron focused on the miniaturization of BNCT systems and the integrated development of hardware, software, and pharmaceutical components. This commercialization process was enabled through a clear division of roles and sustained industry–academia partnership. NTHU contributed core IP, R&D talent, key facilities, and long-term technology collaboration, while Hermes-Epitek, as an early major investor, provided capital, operational expertise, and commercialization channels. This complementary model enabled the transformation of NTHU’s reactor-based neutron source into an accelerator-based BNCT system suitable for hospital deployment.
- In 2023, NTHU’s neutron source received medical device approval from Taiwan’s Food and Drug Administration (TFDA), followed by TFDA approval of Heron’s accelerator-based neutron system in 2024. In 2025, Heron Neutron was listed on the Taiwan Stock Exchange (TWSE). More recently, NTHU and Heron jointly established the Heron–NTHU Joint Research Center to further deepen long-term collaboration in the BNCT field.